Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active | |||
| TBC | avapritinib | Advanced Systemic Mastocytosis | Active | |||
| TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Active | |||
| TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Active | |||
| TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Received | |||
| TBD | Cabozantinib | Withdrawn | ||||
| TBD | Entrectinib | Withdrawn | ||||
| TBD | Rituximab | Cancelled | ||||
| TBD | Trastuzumab | Cancelled | ||||
| TBD | Bevacizumab | Cancelled |
Last Updated : July 28, 2024